Substance

ID:323

Names and Identifiers
Synonyms
Trimethoprim
IUPAC Traditional name
trimethoprim
IUPAC name
5-[(3,4,5-trimethoxyphenyl)methyl]pyrimidine-2,4-diamine
Brand Name
AlprimBactinBactrimBaktarChemotrimCotrim D.S.WellcoprimSyraprimTiempeTrimesulfUnitrimUro-SeptraUroplus DSMonotrimMonotriminProloprimSeptrinSulfatrimSupracombinCotrimFectrimIpralLaratrimTmp-RatiopharmTrimethioprimTrimexazoleTrimogalTrimpex 200TriprimGantaprimImeximLidaprimSeptraSulfatrim PediatricThiocuranAbacinBactraminBactrim PediatricCo-TrimoxazoleComoxDrylinTrimanylTrimeth/SulfaTrimetoprimTrimopanTrimpexUroplus SSSigaprimSulfamethoprim-DSSulfamethoxazole & TrimethoprimSulfotrimSuprimTrigonylMicrotrimMonoprimOraprimPrimoseptSeptra DSSeptra GrapeUroplusAbaprimApo-SulfatrimBactrim DSKepinolSulmeprim PediatricSulprimSumetrolimTeleprimTrimethopriomUretrimPriloprimPrimsolSulfamethoprimSulfatrim-DSSulfatrim-SSSulmeprimEusaprimGantrimIdotrimInstalacMethoprimNopil
Registration numbers
PubChem CID
CAS Number
PubChem SID
Properties
Physical Property
Hydrophobicity(logP)
0.6
Solubility
12.1 mg/mL
Molecule Details
Drug Groups
approved
Description
A pyrimidine inhibitor of dihydrofolate reductase, it is an antibacterial related to pyrimethamine. The interference with folic acid metabolism may cause a depression of hematopoiesis. It is potentiated by sulfonamides and the trimethoprim-sulfamethoxazole combination is the form most often used. It is sometimes used alone as an antimalarial. Trimethoprim resistance has been reported. [PubChem]
Indication
For the treatment of urinary tract infections, uncomplicated pyelonephritis (with sulfamethoxazole) and mild acute prostatitis. May be used as pericoital (with sulfamethoxazole) or continuous prophylaxis in females with recurrent cystitis. May be used as an alternative to treat asymptomatic bacteriuria during pregnancy (only before the last 6 weeks of pregnancy). Other uses include: alternative agent in respiratory tract infections (otitis, sinusitus, bronchitis and pneumonia), treatment of Pneumocystis jirovecii pneumonia (acute or prophylaxis), Nocardia infections, and traveller's diarrhea.
Pharmacology
Trimethoprim is a pyrimidine analogue that disrupts folate synthesis, an essential part of the thymidine synthesis pathway. Inhibition of the enzyme starves the bacteria of nucleotides necessary for DNA replication.The drug, therefore, exhibits bactericidal activity.
Toxicity
LD50=4850 (orally in mice)
Affected Organisms
Gram negative and gram positive bacteria
Biotransformation
Hepatic metabolism to oxide and hydroxylated metabolites.
Absorption
Readily and almost completely absorbed in the GI tract with peak serum concentrations attained 1-4 hours after oral administration. Widely distributed to tissues and fluids including kidney, lung, seminal fluid, aqueous humour, middle ear fluid, sputum, vaginal secretions, bile, bone and CSF.
Half Life
8-11 hours in adults with normal renal function
Protein Binding
42-46% bound to plasma proteins
Elimination
Ten to twenty percent of trimethoprim is metabolized, primarily in the liver; the remainder is excreted unchanged in the urine.
After oral administration, 50% to 60% of trimethoprim is excreted in the urine within 24 hours, approximately 80% of this being unmetabolized trimethoprim. Trimethoprim also passes the placental barrier and is excreted in human milk.
References
• Brumfitt W, Hamilton-Miller JM: Reassessment of the rationale for the combinations of sulphonamides with diaminopyrimidines. J Chemother. 1993 Dec;5(6):465-9. [Pubmed]
• Brumfitt W, Hamilton-Miller JM: Limitations of and indications for the use of co-trimoxazole. J Chemother. 1994 Feb;6(1):3-11. [Pubmed]
• Bean DC, Livermore DM, Papa I, Hall LM: Resistance among Escherichia coli to sulphonamides and other antimicrobials now little used in man. J Antimicrob Chemother. 2005 Nov;56(5):962-4. Epub 2005 Sep 8. [Pubmed]
• Felmingham D, Reinert RR, Hirakata Y, Rodloff A: Increasing prevalence of antimicrobial resistance among isolates of Streptococcus pneumoniae from the PROTEKT surveillance study, and compatative in vitro activity of the ketolide, telithromycin. J Antimicrob Chemother. 2002 Sep;50 Suppl S1:25-37. [Pubmed]
• Johnson JR, Manges AR, O'Bryan TT, Riley LW: A disseminated multidrug-resistant clonal group of uropathogenic Escherichia coli in pyelonephritis. Lancet. 2002 Jun 29;359(9325):2249-51. [Pubmed]
External Links
Molecular Spectra
No Data Available
Click here to submit data
References
• Bean DC, Livermore DM, Papa I, Hall LM: Resistance among Escherichia coli to sulphonamides and other antimicrobials now little used in man. J Antimicrob Chemother. 2005 Nov;56(5):962-4. Epub 2005 Sep 8. Pubmed
• Johnson JR, Manges AR, O'Bryan TT, Riley LW: A disseminated multidrug-resistant clonal group of uropathogenic Escherichia coli in pyelonephritis. Lancet. 2002 Jun 29;359(9325):2249-51. Pubmed
• Brumfitt W, Hamilton-Miller JM: Reassessment of the rationale for the combinations of sulphonamides with diaminopyrimidines. J Chemother. 1993 Dec;5(6):465-9. Pubmed
• Brumfitt W, Hamilton-Miller JM: Limitations of and indications for the use of co-trimoxazole. J Chemother. 1994 Feb;6(1):3-11. Pubmed
• Felmingham D, Reinert RR, Hirakata Y, Rodloff A: Increasing prevalence of antimicrobial resistance among isolates of Streptococcus pneumoniae from the PROTEKT surveillance study, and compatative in vitro activity of the ketolide, telithromycin. J Antimicrob Chemother. 2002 Sep;50 Suppl S1:25-37. Pubmed